Monoamine oxidase inhibitors. A perspective on their use in the elderly

Drugs and Aging

Volumn 13, Issue 5, 1998, Pages 341-355

  Volz, Hans Peter ^a   Gleiter, Christoph H ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; SELEGILINE; TRANYLCYPROMINE; TYRAMINE;

AGED; ANOREXIA; DEPRESSION; DIETARY INTAKE; DRUG SAFETY; DYSKINESIA; GERIATRIC CARE; HUMAN; HYPERTENSION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK; XEROSTOMIA;

EID: 0031783731     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199813050-00002     Document Type: Review

References (74)

1. Greenawalt JW. Localization of monoamine oxidase in rat liver. Adv Biochem Psychopharmacol 1972; 5: 207-26
2. Baker GB, Coutts RT, Young JM, et al. Chronic administration of monoamine oxidase inhibitors: basic and clinical investigations. In: Boulton AA, editor. Neuropharmacology of the trace amines. Clifton: Humana Press, 1985: 317-28
3. Kochersperger LM, Parker EL, Siciliano M, et al. Assignment of genes for human monoaminooxidase A and B to the X chromosome. J Neurosci Res 1986; 16: 602-16
4. Kettler R, Cesura A, Richards JG, et al. Monoaminooxidasehemmer: Neurobiochemie, Wirkungsmechanismus. In: Riederer P, Laux G, Pöldinger W, editors. Neuropsychopharmaka vol. III. Vienna: Springer, 1993: 293-305
5. Strolin-Benedetti M, Dostert P. Overview of the present state of MAO inhibitors. J Neural Transm 1987; 23 Suppl.: 103-19
6. Cesura A, Pletscher A. The new generation of monoamine oxidase inhibitors. Prog Drug Res 1992; 38: 171-297
7. Murphy D, Aulakh CS, Garrick NA, et al. Monoamine oxidase inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 545-52
8. Laux G, Classen W, Sofic E, et al. Clinical, biochemical, and psychometric findings with the new MAO-A inhibitors moclobemide and brofaromine in patients with major depressive disorder. J Neural Transm 1990; 32 Suppl.: 189-95
9. Nakamura S, Kawamata T, Akiguchi I, et al. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol 1990; 80: 319-25
10. Calne DB. The free radical hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992; 32: 804-12
11. Strolin-Benedetti M, Dostert P. Monoamine oxidase, brain aging and degenerative diseases. Biochem Pharmacol 1989; 38: 555-61
12. Gleiter CH, Volz HP. MAO-A inhibitors - state of the art. Exp Opin Invest Drugs 1996; 5: 409-419
13. West ED, Dally PJ. Effects of iproniazid in depressive syndromes. BMJ 1959, 1: 1491-4
14. Raskin A, Schulterbrandt JG, Raetig N, et al. Depression subtypes and response to phenelzine, diazepam and a placebo. Arch Gen Psychiatry 1974; 30: 66-75
15. Laux G, Volz HP, Möller HJ. Newer and older monoamine oxidase inhibitors: a comparative profile. CNS Drugs 1995; 3: 145-58
16. Liebowitz MR, Klein DF. Hysteroid dysphoria. Psychiatr Clin North Am 1979; 2: 555-75
17. Nies A, Robinson DS. Monoamine oxidase inhibitors. In: Paykel ES, editor. Handbook of affective disorders. Edinburgh: Churchill Livingstone, 1982: 246-61
18. Paykel ES, White JL. A European study of views on the use of monoamine oxidase inhibitors. Br J Psychiatry 1989; 155 Suppl. 6: 9-17
19. Liebowitz MR, Hollander E, Schneier F, et al. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr Scand 1990; 360 Suppl.: 29-34
20. Larsen JK. MAOIs in the treatment of depression: a review. Eur J Psychiatry 1991; 5: 79-88
21. Nolen WA, van de Putte JJ, Dijken WS, et al. Treatment strategies in depression: II. MAO inhibitors in depression resistant to cyclic antidepressants. Acta Psychiatr Scand 1988; 78: 676-83
22. Volz HP, Gleiter CH, Möller HJ. Monoamine oxidase inhibitors in psychiatric medicine: the status quo. Nervenarzt 1996; 67: 339-47
23. Tyrer P. Towards rational therapy with monoamine oxidase inhibitors. Br J Psychiatry 1976; 128: 354-60
24. Sheehan DV, Ballenger J, Jacobson G. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry 1980; 37: 51-9
25. Wiseman LR, McTavish D. Selegiline: a review of its clinical efficacy in parkinson's disease and its clinical potential in alzheimer's disease. CNS Drugs 1995; 4: 230-46
26. Lees AJ. Selegeline hydrochloride and cognition. Acta Neurol Scand 1991; 84 Suppl. 136: 91-4
27. Bieck PR, Antonin KH. Tyramine potentiation during treatment with MAO inhibitors hrofaromine and moclobemide vs irreversible inhibitors. J Neural Transm 1989; 28 Suppl.: 21-31
28. Fitton A, Faulds D, Goa KL. Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992; 43: 561-96
29. Sunderland T, Cohen RM, Mochan S, et al. High-dose selegeline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994; 51: 607-15
30. Vestal RE, Montamant SC, Nielson CP. Drugs in special patient groups: the elderly. In: Melmon KL, Morelli HF, Hoffman BB, et al., editors. Melmon and Morellis Clinical Pharmacology. New York: McGraw-Hill, 1992: 851-74
31. Bennett WM, Aronoff GR, Golper TA, et al. Drug prescribing in renal failure. 3rd ed. Philadelphia (PA): American College of Physicians, 1994
32. Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet 1995; 29: 292-332
33. Maguire K, Pereira A, Tiller J. Moclobemide pharmacokinetics in depressed patients: lack of age effect. Hum Psychopharmacol Clin Exp 1991; 6: 249-52
34. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide. Ther Drug Monit 1995; 19: 39-46
35. Volz HP, Gleiter CH, Waldmeier PC, et al. Brofaromine - a review of its pharmacological properties and therapeutic use. J Neural Transm 1996; 103: 217-45
36. Waitzinger J, Ludwig G, Pabst G, et al. Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (1-deprenyl). Int J Clin Pharmacol Ther 1996; 34: 427-32
37. Kerr JS, Fairweather DB, Hindmarch I. The effects of acute and repeated doses of moclobemide on psychomotor performance and cognitive function in healthy elderly volunteers. Hum Psychopharmacol Clin Exp 1992; 7: 273-9
38. Lavie P, Aharon-Peretz J, Klein F, et al. Sleep quality in geriatric depressed patients: comparison with elderly demented patients and normal controls and the effects of moclobemide. Dementia 1992; 3: 360-6
39. Ashford JW, Ford CV. Use of MAO inhibitors in elderly patients. Am J Psychiatry 1979; 136: 1466-7
40. Robinson DS. Monoamine oxidase inhibitors and the elderly. In: Raskin A, Robinson DS, editors. Age and pharmacology of psychoactive drugs. New York: Elsevier, 1981: 151-62
41. Georgotas A, Friedman E, McCarthy M, et al. Resistant geriatric depression and therapeutic response to monoamine oxidase inhibitors. Biol Psychiatry 1983; 18: 195-205
42. Flint AJ, Rifat SL. The effect of sequential antidepressant treatment on geriatric depression. J Affect Disord 1996; 36: 95-105
43. Georgotas A, McCue RE, Hapworth W, et al. Comparative efficacy and safety of MAOIs vs TCAs in treating depression in the elderly. Biol Psychiatry 1986; 21: 1155-66
44. Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 1989; 46: 783-6
45. Georgotas A, McCue RE, Cooper TB, et al. Factors affecting the delay ot antidepressant effect in responders to nortriptyline and phenelzine. Psychiatry Res 1989; 28: 1-9
46. Georgotas A, McCue RE, Friedman E, et al. A placebo-controlled comparison of the effect of nortriptyline and phenelzine on orthostatic hypotension in elderly depressed patients. J Clin Psychopharmacol 1987; 7: 413-6
47. Georgotas A, McCue RE, Cooper TB, et al. How effective and safe is continuation therapy in elderly depressed patients? Factors affecting relapse rate. Arch Gen Psychiatry 1988; 45: 429-32
48. Bugarski-Kirola D, Zivkovic Z, Stankovie Z, et al. Fluoxetine vs moclobemide in elderly depressed patients [abstract]. Eur Neuropsychopharmacol 1996; 6 Suppl. 1: 20
49. De Vanna M, Kummer J, Agnoli A, et al. Moclobemide compared with second-generation antidepressants in elderly people. Acta Psychtatr Scand 1990; 360 Suppl.: 64-6
50. Tiller J, Maguire K, Davies B. A sequential double-blind controlled study of moclobemide and mianserin in elderly depressed patients. Int J Geriatr Psychiatry 1990; 5: 199-204
51. Bocksberger JP, Gachoud JP, Richard J, et al. Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients with a severe depressive episode. Eur Psychiatry 1993; 8: 319-24
52. Pancheri P, Delle Chiaie R, Donnini M, et al. Effects of moclobemide on depressive symptoms and cognitve performance in a geriatric population: a controlled comparative study vs imipramine. Clin Neuropharmacol 1994; 17 Suppl. 1: 58S-73S
53. Nair NPV, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients: a randomized, multicentre trial against placebo. J Affect Disord 1995; 33: 1-9
54. Roth M, Mountjoy R, Amrein R, et al. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry 1996; 168: 149-57
55. Allain H, Cougnard J, Neukirch HC, et al. Selegeline in de novo Parkinsonian patients: the French selegeline multicenter trial (FSMT). Acta Neurol Scand 1991; 84 Suppl. 136: 73-8
56. Allain H, Pollak P, Neukirch HC, et al. Symptomatic effect of selegeline in de novo parkinsonian patients. Mov Disord 1993; 8 Suppl. 1: 36S-40S
57. Shoulson I. An interim report of the effect of selegeline (L-deprenyl) on the progression of disability in early Parkinson's disease. Eur Neurol 1992; 32 Suppl. 1: 46-53
58. The Parkinson Study Group. Effects of deprenyl on the progression of disability in early Parkinsons disease. N Engl J Med 1989; 321: 1364-77
59. Myllylä VV, Sotaniemi KA, Vuorinen JA, et al. Selegeline in de novo Parkinsonian patients: the Finnish study. Mov Disord 1993; 8 Suppl. 1: 41S-4S
60. Chouza C, Aljanati R, Scaramelli A, et al. Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clinical disability in parkinsonian patients. Acta Neurol Scand 1989; 126: 127-37
61. Heinonen EH, Rinne UK, Tuominen J. Selegeline in the treatment of daily fluctuations in disability of Parkinsonian patients with long-term levodopa treatment. Acta Neurol Scand 1989; 126: 113-8
62. Sivertsen B, Dupont E, Mikkelsen B, et al. Selegeline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study. Acta Neurol Scand 1989; 126: 147-52
63. Takahashi M, Yuasa R, Imai T, et al. Selegeline (1-deprenyl) and 1-dopa treatment of Parkinsons disease: a double-blind trial. Intern Med 1994; 33: 517-24
64. Tariot PN, Sunderland T, Weingartner H, et al. Cognitive effects of 1-deprenyl in Alzheimers disease. Psychopharmacology 1987; 91: 489-95
65. Monteverde A, Gnemmi P, Rossi F, et al. Selegeline in the treatment of mild to moderate Alzheimer-type dementia. Clin Ther 1990; 12: 315-22
66. Piccinin GL, Finali G, Piccirilli M. Neuropsychological effects of 1-deprenyl in Alzheimers type dementia. Clin Neuropharmacol 1990; 13: 147-63
67. Mangoni A, Grassi MP, Frattola L, et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol 1991; 31: 100-7
68. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegeline in patients with early, mild Parkinsons disease. BMJ 1995; 311: 1602-7
69. Waters CH. Side effects of selegeline (eldepryl). J Geriatr Psychiatry Neurol 1992; 5: 31-4
70. Noyes MA. Case report of drug-induced serotonin-syndrome in an elderly man [abstract]. Int Pharm Abs 1995; 32: 2355
71. Garcia-Monco J, Padierna A, Beldarrain MG. Selegeline, fluoxetine, and depression in Parkinson's disease [abstract]. Mov Disord 1995; 10: 352
72. Yuh PH, Lai CT, Boulton AA. Effect of adding selegeline to levodopa in early, mild Parkinson's disease: selegeline may be toxic in presence of increased dopamine concentrations [letter]. BMJ 1996; 312: 703-4
73. Jellinger KA. Effect of adding selegeline to levodopa in early, mild Parkinson's disease: causes of death need confirmation [letter]. BMJ 1996; 312: 704-5
74. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa combined with selegeline in patients with early, mild Parkinson's disease. BMJ 1995; 311: 1602-7